Journal of Leukemia & Lymphoma 2022;31(1):11-15

doi:10.3760/cma.j.cn115356-20211217-00297

Application of allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia in the era of targeted therapy

Yingjun CHANG 1 ; Xiangyu ZHAO

Affiliations

+expand

Keywords

Leukemia, lymphocytic, acute; Hematopoietic stem cell transplantation; Chimeric antigen receptor T-cell; Blinatumomab

Country

China

Language

Chinese

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the main curable therapies for patients with acute lymphoblastic leukemia (ALL). This article discusses the status of allo-HSCT for ALL as well as how to combine targeted therapy with allo-HSCT to improve outcomes of ALL in the era of targeted therapy based on the data obtained from the 63rd American Society of Hematology (ASH) Annual Meeting.